Close Menu

Eli Lilly

The Asia Cancer Research Group and BGI plan to collaborate on a project to genomically characterize lung and liver tumors, BGI said last week.

This story originally ran on Dec. 22.
By Adam Bonislawski

By Turna Ray
Qiagen and Eli Lilly have partnered to develop and commercialize a molecular diagnostic that will help pick out best responders to a blood cancer drug that is in early development in Lilly's pipeline.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Qiagen today announced a deal with Eli Lilly to develop a companion diagnostic for an investigational compound the drug manufacturer is developing for blood cancers.

By Adam Bonislawski
Theranostics Health has licensed a new fixative developed by researchers at George Mason University that could significantly improve the quality of tissue samples available to proteomic researchers.

By Adam Bonislawski
Drug companies are no strangers to protein biomarkers, with pharma firms exploring their use for tasks like measuring drug efficacy and selecting patient cohorts for clinical trials.

Thus far, the company has inked collaborative agreements with laboratories at the MD Anderson Cancer Center and Dartmouth Medical College to develop various multi-marker oncology assays; and is pursuing partnerships with pharmaceutical companies to explore using the platform in companion diagnostic development.

Pages

A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.

Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.

Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.

In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.